Sugi Predict

Sugi Predict / Compounds / SCHEMBL1604053

SCHEMBL1604053

SCHEMBL1604053

Cc1sc2ncnc(NC3CCN(C(C)c4cccc(F)c4)CC3)c2c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HTT P42858 3/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ RXFP1 Q9HBX9 2/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ KMT2A Q03164 2/20 0.55
▸ IRAK4 Q9NWZ3 1/20 0.50
▸ MRGPRX1 Q96LB2 1/20 0.43
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPT P10636 4/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CHRM4 P08173 1/20 0.39
▸ MKNK2 Q9HBH9 2/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604243 0.84 MKNK1 (0.55) MAPK1HTTMEN1IRAK4GAA
SCHEMBL1604038 0.81 HTT (0.52) SMN1; SMN2HTTRAB9AMEN1KMT2A
SCHEMBL1604127 0.79 MEN1 (0.49) MEN1KMT2A
Hydrochloric Acid SCHEMBL1920865 0.79 MEN1 (0.49) MEN1KMT2A
SCHEMBL13243175 0.77 CCR5 (0.38) —
SCHEMBL18962385 0.75 MEN1 (0.72) MAPK1SMN1; SMN2HTTRAB9ARXFP1
SCHEMBL1604147 0.74 IRAK4 (0.54) MAPK1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL1606030 0.74 MEN1 (0.53) MAPK1HTTMEN1IRAK4GAA
SCHEMBL1604730 0.72 MKNK1 (0.54) MAPK1SMN1; SMN2HTTMEN1KMT2A
SCHEMBL1604250 0.72 MEN1 (0.67) MAPK1SMN1; SMN2HTTRAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 — — EP disclosed
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 — — EP disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 — — US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 — — EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 — — US disclosed
WO-2009032885-A2 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING FIBROSIS EPIX DELAWARE, INC. (US) 2009-03-12 — — WO disclosed
EP-1622914-A4 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2008-03-12 — — EP disclosed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 — — EP disclosed
US-7030240-B2 5-HT receptor antagonist; [1-(2-Fluoro-benzyl)-piperidin-4-yl]-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine; treating vascular disorders, angina, migraine, pulmonary hypertension and systemic hypertension PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2006-04-18 — — US disclosed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 — — WO disclosed
EP-1622914-A2 NEW PIPERIDINYLAMINO-THIENO 2,3-D PYRIMIDINE COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2006-02-08 — — EP disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 — — US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 — — US disclosed
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2004-12-09 — — US disclosed
WO-2004089312-A2 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis HTR2B, HTR3B, HTR1B MAPK1 3350/4885SMN1; SMN2 2673/4885HTT 2183/4885
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A MAPK1 1254/4885SMN1; SMN2 1416/4885HTT 3169/4885
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds HTR5A, HTR2C, HTR1A MAPK1 1788/4885SMN1; SMN2 1418/4885HTT 1773/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B MAPK1 2155/4885SMN1; SMN2 4727/4885HTT 2061/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B MAPK1 2155/4885SMN1; SMN2 4727/4885HTT 2061/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A MAPK1 1292/4885SMN1; SMN2 1383/4885HTT 3083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.